Latest Tax Incentives News

Page 8 of 64
CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
Victor Sage
21 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
Green360 Technologies has moved MKX further into commercial supply, with binding agreements covering up to 9,600 tonnes and more than 3,500m³ of concrete placed in Melbourne projects. Revenue rose and operating cash outflow narrowed sharply, although the reported contract volumes are maximums rather than guaranteed purchases.
Victor Sage
Victor Sage
20 Oct 2026
Critica’s Jupiter Scoping Study points to a potentially large Western Australian rare earths operation with a modelled pre-tax NPV of A$2.7 billion and after-tax NPV of A$2.0 billion. The headline economics remain preliminary, rely on modelled pricing and tax incentives, and require about A$556 million in pre-production capital that has not yet been secured.
Maxwell Dee
Maxwell Dee
20 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
IODM has posted its strongest-ever September revenue as new university contributions accelerate across the UK and Europe, while its cash position leaves little room for execution missteps. The company ended the quarter with A$747,000 in cash and an estimated 1.2 quarters of funding.
Sophie Babbage
Sophie Babbage
19 Oct 2026
AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
Ada Torres
Ada Torres
19 Oct 2026
Advanced Braking Technology increased Q1 FY27 product sales by 8.3% and ended September with $7.3 million in bank cash. The mining safety company also moved BRAKEiQ closer to CAS Level 9 certification, although the quarter produced a small loss before tax.
Victor Sage
Victor Sage
19 Oct 2026
Latrobe Magnesium says its Phase 1B demonstration plant is 95% installed and 35% commissioned, keeping first magnesium metal crowns above 98% purity on track for the end of 2026. The operational advance comes alongside a tight funding position, an extended A$3.4 million entitlement offer and an ambitious South Carolina expansion plan.
Victor Sage
Victor Sage
16 Oct 2026
Iondrive has formally entered Oklahoma’s Quality Jobs qualification process, advancing potential US$5.2 million in State and local benefits for its first US rare earth recycling module. The broader incentive framework could exceed US$15 million across three modules, but no funding has yet been awarded.
Victor Sage
Victor Sage
16 Oct 2026
Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
Ada Torres
13 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026

Browse the archive

Full archive